Calculation of the Dose of Samarium-153-Ethylene Diamine Tetramethylene Phosphonate (153Sm-EDTMP) as a Radiopharmaceutical for Pain Relief of bone Metastasis
Authors
Abstract:
Introduction One of the important applications of nuclear physics in medicine is the use of radioactive elements as radiopharmaceuticals. Metastatic bone disease is the most common form of malignant bone tumors. Samarium-153-ethylene diamine tetramethylene phosphonate (153Sm-EDTMP) as a radiopharmaceutical is used for pain palliation. This radiopharmaceutical usually emits beta particles, which have a high uptake in bone tissues. The purpose of this study was to calculate the radiation dose distribution of 153Sm-EDTMP in bone and other tissues, using MCNPX Monte Carlo code in the particle transport model. Materials and Methods Dose delivery to the bone was simulated by seeking radiopharmaceuticals on the bone surface. The phantom model had a simple cylindrical geometry and included bone, bone marrow, and soft tissue. Results The simulation results showed that a significant amount of radiation dose was delivered to the bone by the use of this radiopharmaceutical. Conclusion Thebone acted as a fine protective shield against rays for the bone marrow. Therefore, the trivial absorbed dose by the bone marrow caused less damage to bone-making cells. Also, the high absorbed dose of the bone could destroy cancer cells and relieve the pain in the bone.
similar resources
calculation of the dose of samarium-153-ethylene diamine tetramethylene phosphonate (153sm-edtmp) as a radiopharmaceutical for pain relief of bone metastasis
introduction one of the important applications of nuclear physics in medicine is the use of radioactive elements as radiopharmaceuticals. metastatic bone disease is the most common form of malignant bone tumors. samarium-153-ethylene diamine tetramethylene phosphonate (153sm-edtmp) as a radiopharmaceutical is used for pain palliation. this radiopharmaceutical usually emits beta particles, which...
full textProduction of 177Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical
Background: Owing to its favourable decay characteristics 177Lu [T1/2= 6.71 d, Eβ(max)= 497 keV] is an attractive radionuclide for various therapeutic applications. Ethylene diamine tatramethylene phosphonate (EDTMP) is one of the most widely used ligands which form stable complexes with various radionuclides and all the complexes. Materials and Methods: Enriched 176Lu2O3 was dissolve...
full textSamarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases
Bone metastases are prevalent among cancer patients and frequently cause significant morbidity. Oncology providers must mitigate complications associated with bone metastases while limiting therapy-related adverse effects and their impact on quality of life. Multiple treatment modalities, including chemotherapy, surgery, external beam radiation therapy, and radioisotopes, among others, have bee...
full textHigh-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
PURPOSE Samarium-153 ethylene diamine tetramethylene phosphonate ((153)Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradiation to osteoblastic bone metastases. Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer. P...
full textproduction of 177lu and formulation of ethylene diamine tetramethylene phosphonate (edtmp) kits as a bone-seeking radiopharmaceutical
background: owing to its favourable decay characteristics 177lu [t1/2= 6.71 d, eβ(max)= 497 kev] is an attractive radionuclide for various therapeutic applications. ethylene diamine tatramethylene phosphonate (edtmp) is one of the most widely used ligands which form stable complexes with various radionuclides and all the complexes. materials and methods: enriched 176lu2o3 was dissolved in 0.1 n...
full textInternal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP).
Fifteen dogs were referred because of a spontaneous bone tumor, lameness, and local pain. The osteosarcoma diagnosis was established by clinical examination, X-ray, bone scintigraphy, and histological examination of biopsy material. The tumors were located in the extremities (n = 12), scapula (n = 1), maxilla (n = 1), and the frontal bone (n = 1). The dogs were given one to four i.v. injections...
full textMy Resources
Journal title
volume 12 issue 4
pages 278- 283
publication date 2015-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023